Navigation Links
TGen, Virginia G. Piper Cancer Center scientist heads lung cancer consortium
Date:6/8/2011

SCOTTSDALE, Ariz. June 8, 2011 Dr. Glen Weiss, who holds joint appointments at the Translational Genomics Research Institute (TGen) and at the Virginia G. Piper Cancer Center at Scottsdale Healthcare, is the new Chief Medical Officer of an international lung cancer research consortium.

In this new position, Dr. Weiss heads the Cancer Research and Biostatistics-Clinical Trials Consortium (CRAB-CTC), a Seattle-based cooperative research network, created by a group of preeminent lung cancer investigators. It represents more than 10 institutes worldwide dedicated to funding and facilitating clinical trials, thereby providing lung cancer patients with newly developed therapeutics as quickly as possible.

"Our Consortium's explicit mission is to organize and accelerate the clinical development of new agents for the treatment of patients with lung cancer," said Dr. Weiss, an Assistant Professor of TGen's Cancer and Cell Biology Division. He also is Director of Thoracic Oncology at Virginia G. Piper Cancer Center Clinical Trials, a partnership between TGen and Scottsdale Healthcare that treats cancer patients with promising new drugs through clinical trials at the Virginia G. Piper Cancer Center in Scottsdale, Ariz.

CRAB-CTC members include laboratory and clinical researchers in the U.S., Canada and China who share a passion for bringing new scientific advances to patients with lung cancer as rapidly as possible.

"Our Consortium provides a well-coordinated effort dedicated to rapidly translating research discoveries into new treatments and supportive care for patients with lung cancer," said Dr. Weiss.

Unlike similar research consortiums, CRAB-CTC is not affiliated or funded by government, but works directly with pharmaceutical firms to advance their compounds.

"CRAB's mission is to help conquer cancer. The network provided by the CRAB-CTC enables research oncologists to design and conduct innovative studies more quickly, in more places and with greater degree of opportunity for specific patient needs," said Dr. John Crowley, CEO of CRAB and lead statistician for multiple cancer clinical trials.

"What this will mean for patients, is that we will be able to offer patients new therapies much faster," Dr. Weiss said.


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related biology news :

1. TGen, Scottsdale Healthcare, Mayo Clinic study new drug to stimulate immune system of cancer victims
2. Virginia Tech mechanical engineers win measurement science best paper award
3. Virginia Tech announces football helmet ratings for reducing concussion risk
4. Young scientist at Virginia Commonwealth University wins Avanti prize
5. Virginia Tech forest researcher awarded NSF early career grant
6. Virginia Tech researcher seeks to use electrical stimulation to give voice to stroke patients
7. Virginia Tech shares in grant to study effects of climate change on southern pine forests
8. Virginia Tech engineer identifies new concerns for antibiotic resistance, pollution
9. Virginia Tech engineers introduce thermotherapy as a chemotherapy alternative
10. USDA awards Virginia Tech $3.8 million to stimulate eastern US wine industry
11. Virginia Tech studies impact of Gulf oil spill on plovers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... Securus Technologies, a leading provider of ... safety, investigation, corrections and monitoring, and the Prison ... (5) year funding commitment by Securus to PEP ... and reentry support to more inmates and their ... the Prison Entrepreneurship Program (PEP) is an independent ...
(Date:12/2/2016)...   SoftServe , a global digital technology ... electrocardiogram (ECG) biosensor analysis system for continuous driver ... The smart system ensures device-to-device communication between ECG ... mobile devices to easily ,recognize, and monitor users ... technology advances, so too must the security systems ...
(Date:11/29/2016)... Nov. 29, 2016 BioDirection, a privately held ... for the objective detection of concussion and other traumatic ... successfully completed a meeting with the U.S. Food and ... test Pre-Submission Package. During the meeting company representatives reviewed ... a precursor to commencement of a planned pilot trial. ...
Breaking Biology News(10 mins):
(Date:12/7/2016)... PA (PRWEB) , ... December 07, 2016 , ... ... website, http://www.autoreactors.com and online shopping cart. The new website has been ... functionality. These essential digital components allow customers to access detailed product information, read ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... privately-held contract pharmaceutical development and manufacturing organisation, today announced the formation ... combining a leading CRO and the industry’s only Contract Commercial Organization (CCO). ...
(Date:12/6/2016)... (PRWEB) , ... December 06, ... ... a Great Point Partners ("GPP") portfolio company, today announced it has acquired ... previously a subsidiary of Chiltern International and focuses on clinical trial drug ...
(Date:12/6/2016)... , Dec. 6, 2016  The Texas ... Society of Australia (HISA) today announced the establishment ... exchange program between Australia and ... the world. HISA and the Texas ... a program to create a global health innovation ecosystem ...
Breaking Biology Technology: